SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SOUTH SAN FRANCISCO, Calif., March 01, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two upcoming investor conferences.
- Sean McCarthy, D. Phil., president and chief executive officer, will present at the Cowen and Company 38th Annual Healthcare Conference on March 13, 2018, at 10:00 a.m. ET.
- Debanjan Ray, Chief Financial Officer and Head of Corporate Development, will present at the Barclay’s Global Health Conference on March 15, 2018, at 8:30 a.m. ET.
A live audio webcast for each event will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic and BMS-986249, a CTLA-4-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Media:
Spectrum
Christine Quern
[email protected]
202-587-2588
Investors:
Trout Group
Pete Rahmer
[email protected]
646-378-2973
